重庆医学2024,Vol.53Issue(10) :1557-1562.DOI:10.3969/j.issn.1671-8348.2024.10.021

心肌梗死外泌体miRNA及外泌体无细胞疗法的研究进展

Research progress of exosome miRNA and exosome cell-free therapy in myocardial infarction

吴新宇 李静茹 王路乔
重庆医学2024,Vol.53Issue(10) :1557-1562.DOI:10.3969/j.issn.1671-8348.2024.10.021

心肌梗死外泌体miRNA及外泌体无细胞疗法的研究进展

Research progress of exosome miRNA and exosome cell-free therapy in myocardial infarction

吴新宇 1李静茹 1王路乔1
扫码查看

作者信息

  • 1. 昆明医科大学第一附属医院心血管内科,昆明 650032
  • 折叠

摘要

心肌梗死(MI)是冠状动脉持续缺血缺氧引起的不可逆性心肌损伤,严重威胁人们的生命健康.外泌体是多泡体与质膜融合后释放到周围体液中的纳米级双层脂质囊泡,作为外泌体内含的重要生物活性分子,miRNA通过改变多种生物学途径来调控MI的病理机制.外泌体具有稳定性高、毒性小、剂量可控等优点,负载miRNA的外泌体无细胞疗法应运而生.该文综述了外泌体miRNA在MI中的诊疗及预后价值,并对外泌体无细胞疗法的应用前景和局限性进行了讨论.

Abstract

Myocardial infarction(MI)is an irreversible myocardial injury caused by continuous ische-mia and hypoxia of coronary arteries,which seriously threatens people's life and health.Exosomes are nanoscale bilayer lipid vesicles released into the surrounding body fluids after the fusion of multivesicular bodies and plasma membranes.As an important bioactive molecule contained in exosomes,miRNAs regulate the pathological mechanism of MI by changing various biological pathways.Exosomes have the advantages of high stability,low toxicity,and controllable dose.Exosome-based cell-free therapy loaded with miRNA has e-merged.This article reviewed the diagnostic and prognostic value of exosome miRNA in MI,and discussed the application prospects and limitations of exosomal cell-free therapy.

关键词

外泌体/微小RNA/心肌梗死/生物标志物/调控机制/综述

Key words

exosomes/miRNA/myocardial infarction/biomarkers/regulation mechanism/review

引用本文复制引用

基金项目

国家自然科学基金(81860073)

国家自然科学基金(82360076)

云南省应用基础计划面上项目(202001AT070039)

云南省应用基础计划面上项目(202301AT070200)

云南省科技厅-昆明医科大学应用基础研究联合专项(2019FE001-138)

云南省千人计划-青年人才专项(RLQN20200002)

云南省高层次卫生计生技术人才培养经费资助项目(H-2018032)

昆明医科大学研究生创新基金(2022)(2022S035)

出版年

2024
重庆医学
重庆市卫生信息中心,重庆市医学会

重庆医学

CSTPCD
影响因子:1.797
ISSN:1671-8348
参考文献量42
段落导航相关论文